Ascentage Pharma (AAPG) said Monday that two of its drug candidates, lisaftoclax and olverembatinib, were included in the 2025 Chinese Society of Clinical Oncology Guidelines.
The company said lisaftoclax is first recommended in the CSCO guidelines as a potential treatment for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
The investigational drug is currently under priority review in China following a November 2024 new drug application, Ascentage said.
Olverembatinib received an upgraded recommendation for use in children with leukemia and retained several existing recommendations for adult leukemia treatment, according to the company.
Ascentage said the drug remains part of China's national reimbursement drug list and is co-marketed in the country with Innovent Biologics.
The investigational drugs have not been approved in the US, Ascentage added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。